Equities research analysts expect Alpine Immune Sciences Inc (NASDAQ:ALPN) to post $370,000.00 in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Alpine Immune Sciences’ earnings. The highest sales estimate is $500,000.00 and the lowest is $300,000.00. Alpine Immune Sciences posted sales of $130,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 184.6%. The company is expected to issue its next earnings results on Wednesday, March 27th.

According to Zacks, analysts expect that Alpine Immune Sciences will report full-year sales of $1.24 million for the current year, with estimates ranging from $710,000.00 to $1.61 million. For the next fiscal year, analysts anticipate that the business will report sales of $1.42 million, with estimates ranging from $1.00 million to $2.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.31). Alpine Immune Sciences had a negative return on equity of 26.00% and a negative net margin of 1,602.19%.

ALPN has been the subject of a number of research reports. Zacks Investment Research raised shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, July 25th. ValuEngine raised shares of Alpine Immune Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 26th. Raymond James initiated coverage on shares of Alpine Immune Sciences in a research note on Monday, August 13th. They issued a “buy” rating and a $13.00 price objective for the company. Finally, Piper Jaffray Companies initiated coverage on shares of Alpine Immune Sciences in a research note on Thursday, September 27th. They issued an “overweight” rating and a $12.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $12.67.

NASDAQ:ALPN traded down $0.01 during mid-day trading on Wednesday, reaching $4.80. The company’s stock had a trading volume of 9,821 shares, compared to its average volume of 15,467. Alpine Immune Sciences has a 1 year low of $4.61 and a 1 year high of $11.75. The firm has a market cap of $66.77 million, a PE ratio of -4.00 and a beta of 0.94. The company has a debt-to-equity ratio of 0.05, a current ratio of 20.99 and a quick ratio of 20.99.

A number of large investors have recently added to or reduced their stakes in ALPN. DRW Securities LLC raised its holdings in Alpine Immune Sciences by 138.7% in the second quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 14,143 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Alpine Immune Sciences by 122.2% in the second quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 18,052 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Alpine Immune Sciences by 20.9% in the second quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after purchasing an additional 21,124 shares in the last quarter. 56.87% of the stock is owned by institutional investors.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

See Also: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.